Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) — Board Meeting(3 announcements)

Jagsonpal Pharmaceuticals announced the appointment of Anil Kumar Matai as an additional independent director effective June 25, 2026, for a five-year term subject to shareholder approval. The board approved the appointment during a meeting held on June 25, 2026, from 4:45 p.m. to 5:30 p.m. Mr. Matai brings over 35 years of experience in multinational pharmaceuticals, including leadership roles at Novartis India and Zydus Healthcare, and currently serves as Director General of OPPI. His appointment aims to strengthen governance and strategic oversight in the life sciences sector.

Jagsonpal Pharmaceuticals announced the appointment of Anil Kumar Matai as an Independent Director effective June 25, 2026, for a five-year term pending shareholder approval. His extensive life sciences background includes leadership roles at Novartis India and Zydus Healthcare, and current position as OPPI Director General.

Jagsonpal Pharmaceuticals announced the appointment of Anil Kumar Matai as an independent director effective June 25, 2026, for a five-year term subject to shareholder approval. The board approved the appointment at a meeting held on June 25, 2026, from 4:45 p.m. to 5:30 p.m. The filing confirms no familial relationships exist between Mr. Matai and other board members and includes his professional background in life sciences leadership.